#None #Chicago #AbbVie #Skyrizi #RINVOQ

AbbVie Showcases Significant Developments in IBD Treatments at DDW 2026

AbbVie has made headlines at the 2026 Digestive Disease Week (DDW), held from May 2-5 in Chicago, by presenting critical insights into its gastroenterology portfolio. The pharmaceutical giant unveiled 18 abstracts that emphasize the effectiveness of its leading therapies, SKYRIZI (risankizumab) and RINVOQ (upadacitinib), particularly for patients suffering from Crohn's disease and ulcerative colitis.

Highlights from the Presentation

The focus of AbbVie's presentation highlights the sustained efficacy and safety of both SKYRIZI and RINVOQ, reinforcing their roles as standard-bearers in the treatment of Inflammatory Bowel Diseases (IBD). Dr. Andrew Anisfeld, AbbVie’s Vice President of Global Medical Affairs, noted that their research continues to illuminate ways to enhance care standards through innovative therapies.

Real-World Evidence on SKYRIZI in Crohn's Disease

One compelling study presented at the event involved a 52-week follow-up of adults with moderate to severe Crohn's disease treated with SKYRIZI. The findings showcased significant and sustained improvements across key symptoms, including notable reductions in abdominal pain and bowel urgency.

Particularly striking was the relief experienced by patients with extraintestinal manifestations of the disease. Reports indicated that 25% of arthritis sufferers and an impressive 46% of those with skin conditions acknowledged symptom relief after a year on treatment. Furthermore, the need for corticosteroids dropped drastically among these patients—from 34% at baseline to just 7% after 52 weeks.

Quality of Life Improvements

Another investigation was aimed at understanding the health-related quality of life (HRQL) and treatment satisfaction among patients beginning treatment with SKYRIZI. The outcomes were encouraging: 77% of participants reported a greater enjoyment in life after one year of treatment. Improvements were also seen in professional productivity and overall daily activities, with patient satisfaction soaring from 50% at the start of treatment to nearly 87% after 52 weeks, reflecting the profound impact of effective management in IBD.

Switch Rates and Persistence of Treatment

AbbVie also analyzed treatment persistence, revealing a relatively low switch rate of only 14% for patients on SKYRIZI, especially in comparison to other biologic therapies, like ustekinumab and vedolizumab, which had switch rates of 21% and 30%, respectively. This data underscores SKYRIZI’s standing as a preferred therapy among patients.

Advantages of Switching to RINVOQ

As part of the presentation, AbbVie discussed findings from a retrospective analysis indicating that patients who switched to RINVOQ exhibited a significant reduction in hospitalization rates—31% lower than patients who merely escalated their current biologic treatments. This insight reinforces the potential benefits of transitioning to RINVOQ as a more effective treatment strategy.

Endoscopic Improvements in Challenging Cases

The event also highlighted the efficacy of RINVOQ in patients with difficult-to-treat Crohn's disease, particularly those suffering from perianal fistulizing disease. Results from two Phase 3 trials indicated that participants treated with RINVOQ showed notable endoscopic improvements, regardless of preceding anti-TNF therapy response—a significant milestone for managing therapeutic challenges in this patient cohort.

Future Directions

AbbVie is actively pursuing further advancements, having recently submitted an application to the FDA for SKYRIZI to be utilized as an induction therapy for adults grappling with moderate to severe active Crohn's disease.

The comprehensive data and findings presented at the 2026 DDW serve not only as a testament to AbbVie’s ongoing commitment but also emphasize the critical need for continued innovation in therapies targeting chronic conditions like IBD, ultimately aimed at enhancing the lives of millions grappling with these diseases.

Conclusion

AbbVie’s contributions at the Digestive Disease Week encapsulate a significant commitment to enhancing treatment standards for IBD. The robust data shared on SKYRIZI and RINVOQ demonstrates not only their effectiveness but also their potential to transform patient experiences and outcomes across the spectrum of inflammatory bowel diseases.